Global Asymmetries in Spinocerebellar Ataxia Research: A Critical Review of Epidemiological, Diagnostic and Translational Challenges

Abstract

Spinocerebellar ataxias are a genetically heterogeneous group of dominantly inherited neurodegenerative disorders in which progressive cerebellar dysfunction is accompanied by variable extracerebellar involvement. Three decades of molecular work have produced an unusually detailed map of causative loci, yet the global picture of the disease group remains distorted by the geography of research itself. This critical narrative review examines how the concentration of cohorts, biobanks, sequencing capacity and clinical trials in a small number of high-income settings shapes what is currently known about occurrence, phenotype, progression and treatment response, and how that concentration constrains the inferences that can defensibly be drawn. Evidence was identified through structured searching of scholarly databases and indexes, supplemented by citation tracking, with the final search conducted on 21 June 2026. The synthesis is organised around five problems: the fragility of prevalence estimation outside a handful of well-characterised populations; the reordering of the nosology after the recognition of intronic repeat expansions and the emergence of late-onset forms that were previously invisible; the persistent distance between mechanistic models derived from rodent and cellular systems and the clinical course observed in patients; the incomplete validation of clinical, fluid, imaging and digital outcome measures across genotypes and populations; and the mismatch between an expanding preclinical therapeutic pipeline and a small number of adequately powered human trials. Convergent findings support genotype-specific progression rates, the prognostic value of neurofilament light chain and regional brain volumes, and the value of rehabilitation, while evidence for symptomatic pharmacology and non-invasive neuromodulation remains inconsistent. Several widely repeated claims, including uniform subtype frequencies and the interchangeability of outcome measures across cohorts, are not supported by the primary data. Priorities include population-representative epidemiological work in underrepresented regions, harmonised and genotype-specific endpoint validation, prospective study of somatic repeat instability, and trial designs that accommodate slowly progressive phenotypes.